Form 4: Natera Legal Officer Sells Shares for Tax Obligations Under 10b5-1 Plan

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, sold 1,994 shares of common stock to cover tax obligations related to RSU vesting, as disclosed in a recent Form 4 filing.

Summary

• Daniel Rabinowitz, Natera's SEC and Chief Legal Officer, sold 1,994 shares of Natera common stock.
• The sale occurred on July 28, 2025, at a price of $139.8083 per share.
• The transaction was executed to satisfy tax withholding and remittance obligations arising from the vesting of Restricted Stock Units (RSUs).
• The sale was conducted under a Rule 10b5-1 pre-arranged trading plan, specifically from Stock Unit Agreements granted on January 27, 2023, and January 26, 2024.
• Following this transaction, Daniel Rabinowitz beneficially owns 202,164 shares of Natera common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, executed under a Rule 10b5-1 plan. This is a neutral event and does not indicate positive or negative sentiment towards the company's future prospects.

Positives

• The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 plan, indicating it was for tax purposes rather than a lack of confidence in the company.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs.
• The sale was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Industry Context

This filing is a routine insider transaction for tax purposes and does not provide broader insights into industry trends or competitive landscape. It reflects standard compensation practices involving equity awards in the biotechnology or diagnostics industry.

Comparison to Industry Standards

• The transaction is a standard practice for executives receiving equity compensation, where a portion of vested shares are sold to cover tax liabilities.
• This is common across publicly traded companies, including peers in the diagnostics and genetic testing sector such as Illumina (ILMN), Guardant Health (GH), or Exact Sciences (EXAS), where executives often utilize Rule 10b5-1 plans for such purposes.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence. The number of shares sold is small relative to the total outstanding shares and the insider's remaining holdings.

Key Dates

Keywords

Natera, NTRA, Insider Trading, Form 4, Stock Sale, Daniel Rabinowitz, Restricted Stock Units, RSU, Tax Obligations, Rule 10b5-1